{
    "eid": "2-s2.0-85136240517",
    "title": "Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials",
    "cover-date": "2023-03-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Health Policy",
            "@code": "2719",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Asian",
        "Bictegravir",
        "HIV",
        "regimen switch",
        "safety",
        "virologically suppressed"
    ],
    "authors": [
        "Anchalee Avihingsanon",
        "Ploenchan Chetchotisakd",
        "Sasisopin Kiertiburanakul",
        "Winai Ratanasuwan",
        "Krittaecho Siripassorn",
        "Khuanchai Supparatpinyo",
        "Hal Martin",
        "Hui Wang",
        "Tin Hung Wong",
        "Hsiu Yin Wang"
    ],
    "citedby-count": 0,
    "ref-count": 34,
    "ref-list": [
        "Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection",
        "Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial",
        "Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society\u2013USA panel",
        "Zhonghua Nei Ke Za Zhi",
        "Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial",
        "Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial",
        "Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials",
        "Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial",
        "Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial",
        "Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial",
        "Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial",
        "Impact of small body weight on Tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients",
        "Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up",
        "Low body weight and tenofovir use are risk factors for renal dysfunction in Vietnamese HIV-infected patients. A prospective 18-month observation study",
        "A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions",
        "Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study",
        "A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206",
        "The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV",
        "Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials",
        "Long-term weight gain after initiating combination antiretroviral therapy in treatment-na\u00efve Asian people living with human immunodeficiency virus",
        "Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy",
        "Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials",
        "Metabolic effects of preexposure prophylaxis with coformulated Tenofovir Disoproxil fumarate and emtricitabine",
        "Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial",
        "CYP2B6 genotype and weight gain differences between Dolutegravir and Efavirenz"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60032250",
            "affilname": "Faculty of Medicine, Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032250",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60026046",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60015887",
            "affilname": "Faculty of Medicine Ramathibodi Hospital, Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015887",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Foster City",
            "@id": "60002909",
            "affilname": "Gilead Sciences Incorporated",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "128478852",
            "affilname": "Gilead Sciences",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/128478852",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "122211284",
            "affilname": "Gilead Sciences",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122211284",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Nontaburi",
            "@id": "106545448",
            "affilname": "Bamrasnaradura Infectious Diseases Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/106545448",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "GSK",
        "Gilead Sciences",
        "MSD"
    ]
}